Compare Sterling Biotech with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ORCHID PHARMA LTD - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ORCHID PHARMA LTD STERLING BIOTECH/
ORCHID PHARMA LTD
 
P/E (TTM) x -0.4 -0.5 - View Chart
P/BV x 0.0 0.1 12.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   ORCHID PHARMA LTD
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ORCHID PHARMA LTD
Sep-13
STERLING BIOTECH/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs11194 5.4%   
Low Rs335 9.7%   
Sales per share (Unadj.) Rs26.8276.5 9.7%  
Earnings per share (Unadj.) Rs-15.0-79.2 18.9%  
Cash flow per share (Unadj.) Rs-5.5-43.5 12.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.953.9 101.8%  
Shares outstanding (eoy) m267.8770.45 380.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.30.4 62.6%   
Avg P/E ratio x-0.5-1.4 32.1%  
P/CF ratio (eoy) x-1.3-2.6 48.3%  
Price / Book Value ratio x0.12.1 6.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,8628,067 23.1%   
No. of employees `0001.42.8 48.4%   
Total wages/salary Rs m5472,527 21.6%   
Avg. sales/employee Rs Th5,303.36,956.1 76.2%   
Avg. wages/employee Rs Th403.8902.5 44.7%   
Avg. net profit/employee Rs Th-2,959.0-1,993.0 148.5%   
INCOME DATA
Net Sales Rs m7,18119,477 36.9%  
Other income Rs m43407 10.5%   
Total revenues Rs m7,22319,884 36.3%   
Gross profit Rs m9471,103 85.9%  
Depreciation Rs m2,5432,519 101.0%   
Interest Rs m4,3775,227 83.7%   
Profit before tax Rs m-5,931-6,236 95.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m-1,924-125 1,537.0%   
Profit after tax Rs m-4,007-5,580 71.8%  
Gross profit margin %13.25.7 232.9%  
Effective tax rate %32.42.0 1,616.1%   
Net profit margin %-55.8-28.7 194.7%  
BALANCE SHEET DATA
Current assets Rs m14,33511,014 130.1%   
Current liabilities Rs m49,80932,060 155.4%   
Net working cap to sales %-494.0-108.1 457.2%  
Current ratio x0.30.3 83.8%  
Inventory Days Days40395 425.2%  
Debtors Days Days17134 508.5%  
Net fixed assets Rs m55,43229,440 188.3%   
Share capital Rs m268705 38.0%   
"Free" reserves Rs m13,9352,043 682.2%   
Net worth Rs m14,7013,800 386.9%   
Long term debt Rs m9,4789,018 105.1%   
Total assets Rs m73,98846,510 159.1%  
Interest coverage x-0.4-0.2 183.8%   
Debt to equity ratio x0.62.4 27.2%  
Sales to assets ratio x0.10.4 23.2%   
Return on assets %0.5-0.8 -65.9%  
Return on equity %-27.3-146.9 18.6%  
Return on capital %-6.4-3.7 172.1%  
Exports to sales %25.937.9 68.4%   
Imports to sales %0.222.6 0.8%   
Exports (fob) Rs m1,8607,378 25.2%   
Imports (cif) Rs m124,406 0.3%   
Fx inflow Rs m1,8607,513 24.8%   
Fx outflow Rs m255,649 0.4%   
Net fx Rs m1,8351,865 98.4%   
CASH FLOW
From Operations Rs m1,7191,682 102.2%  
From Investments Rs m-3,148-9,860 31.9%  
From Financial Activity Rs m1,4266,644 21.5%  
Net Cashflow Rs m-3-1,535 0.2%  

Share Holding

Indian Promoters % 33.9 32.3 105.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.6 -  
FIIs % 9.9 3.3 300.0%  
ADR/GDR % 16.9 4.6 367.4%  
Free float % 39.3 55.3 71.1%  
Shareholders   21,482 84,811 25.3%  
Pledged promoter(s) holding % 55.9 54.9 101.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   CIPLA  SANOFI INDIA  ALKEM LABORATORIES  SUN PHARMA  PFIZER  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - AUROBINDO PHARMA COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS